Biolife solutions makes strategic investment in pluristyx

Bothell, wash. , july 28, 2025 /prnewswire/ -- biolife solutions, inc. (nasdaq: blfs), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("cgt") market, today announced that as part of a larger round of financing it has purchased $2 million of convertible notes in pluristyx, inc. ("pluristyx"), a seattle based developer of innovative induced pluripotent stem cell (ispc) based products for cell therapy developers.
BLFS Ratings Summary
BLFS Quant Ranking